VCU Massey Cancer Center physician-researcher Charles Geyer, M.D., co-developed and co-led two important national breast cancer clinical trials that were recently presented at the American Society of Clinical Oncology’s annual meeting in Chicago. One study was presented in the “Best of ASCO” Program, which presents the scientific and educational highlights of the meeting.
In March of 2003, I was having pain in my right upper chest that initially occurred only when I laughed. Eventually the pain continued to worsen, so I made an appointment with my primary care physician. After many tests and procedures, fluid-filled sacks were found on my liver. The following week, I was scheduled for a liver biopsy.
I woke up from that biopsy and my life had been changed forever.
Novel combination therapy developed at Massey shows strong response in patients with advanced solid tumors
A phase 1 clinical trial testing a novel combination therapy developed by scientists at VCU Massey Cancer Center slowed the growth of cancer in the majority of trial participants, which were patients with advanced solid tumors. Approximately 61 percent of these patients experienced some degree of tumor growth delay, with multiple partial responses and one complete response. A phase 2 study testing the same combination of the drugs sorafenib and pemetrexed in patients with recurrent or metastatic triple negative breast cancer is now open at Massey.
This month’s recipes continue in the same vein as last month’s: they both “fit the bill” when it comes to adding fiber-rich foods to your diet. The split pea soup recipe also incorporates some vegetables into the dish, and a slice of the seeded whole grain quick bread can meet one of your daily servings for whole grains recommended by American Institute for Cancer Research.
VCU Massey researchers encouraged by Vice President Biden’s $70 million Genomics Data Commons project
Researchers from Virginia Commonwealth University (VCU) Massey Cancer Center were in attendance at the American Society for Clinical Oncology’s annual meeting in Chicago when Vice President Joe Biden announced that more than $70 million would be invested in the development of the Genomics Data Commons (GDC), an information center housed at the University of Chicago and funded by the National Cancer Institute (NCI) to help facilitate the sharing of genomic and clinical data among cancer researchers in order to advance personalized medicine.